Sinovac Biotech, Ltd. · NASDAQ:SVA
Sinovac Biotech — Investor Presentation (October 2010)
22 slides from Sinovac Biotech's investor presentation, October 2010
Slide 1: Sinovac Biotech Ltd. October 2010
Sinovac Biotech Ltd. October 2010
Slide 2: Disclaimer
Disclaimer This presentation does not constitute an offer to sell or issue, or the solicitation of an offer to buy or acquire securities of Sinovac Biotech Ltd. (the “Company”) in any jurisdiction, or an inducement to enter into investment activity, nor may it or any part of it form the basis of or
Slide 3: Company Overview and Key Milestones
Company Overview Key Milestones Founded in 2001, headquartered in Beijing Established Sinovac (Dalian) Vaccine Fully integrated, profitable China-based Technology Co., Ltd. biopharmaceutical company focused on researching, Completed acquisition of Changping 2010 buildings and land developing, ma
Slide 4: Our Mission
Our Mission Supply Vaccines To Eliminate Human Diseases • Provide Chinese children with world class vaccines • Benefit children worldwide with vaccines made in China After sales R&D Production Sales & Marketing Customer Services 4
Slide 5: Sinovac Organizational Structure
Sinovac Organizational Structure Retail Investors: 62.8% Insiders 11.4%1 Institutional Investors: Retail Investors: Dr. Weidong Yin (Chairman): 11%1 36.4%1 52.2%1 Sinovac Biotech Ltd. NASDAQ:SVA 100% Sinovac Biotech（Hong Kong) Ltd. SinoBioWay Jin Gang Group 100% 28.44% 71.56% 55.0% 45.0% 100%
Slide 6: Advanced Manufacturing Facilities with Stringent Quality Assurance
Advanced Manufacturing Facilities with Stringent Quality Assurance Manufacturing Plants Dalian: Vero Cell Cultured Vaccine Beijing and Live Attenuated Vaccine Headquarters (95,000 square meters) Dalian Beijing Tangshan Changping District, Beijing Vaccine Production Center Tangshan Yian Animal (29,00
Slide 7: China Vaccine Market Poised for Strong Growth
China Vaccine Market Poised for Strong Growth Increased Government Spending on Strong Government Support of Expanded Program of Immunization (EPI) Disease Prevention RMB218m (US$32m) in 2004 to RMB2.8b (US$412m) in 2007 ~RMB10bn (US$1.5bn) allocated Coverage increased to 14 vaccines to R&D of
Slide 8: Focus on Five Key Strategic Objectives
Focus on Five Key Strategic Objectives Develop new products to serve unmet market needs Expand production capacity to serve growing demand from China and other developing markets Sinovac aims to: Develop more products against more types of disease Improve product quality to international standards P
Slide 9: Current Product Portfolio
Current Product Portfolio Healive (Hep A) Vaccine Bilive (Hep A & B) Vaccine 1st inactivated Hepatitis A vaccine developed, Largest combined inactivated hepatitis A and B produced, and marketed by a Chinese manufacturer vaccine supplier in China Hepatitis A vaccine included in EPI since Feb. 2008 Ma
Slide 10: Well-Established Sales, Marketing and Distribution Network
Well-Established Sales, Marketing and Distribution Network Largest supplier in Favorable selling Public Successful sales in Beijing, Shanghai, public market of price among inactivated Market Tianjin and Jiangsu hepatitis A vaccine competition with comfortable margin 145 Private Representatives 31 Pr
Slide 11: Organic Growth from Current Product Offering
Organic Growth from Current Product Offering Healive (Hep A) Vaccine 2009 Healive Market Share Berna 6,900 7,000 Changsheng 1% 5,900 7% GSK Thousand Doses 6,000 10% Kunming 5,100 30% 5,000 Pukang 4,000 14% 2,600 3,000 Changchun Sinovac 2,000 1,300 500 1,000 16% 22% 1,000 - 2003 2004 2005 2006 2007 2
Slide 12: Production and Quality Control Management
Production and Quality Control Management Producing high quality vaccines with favorable stability and safety profile and with no serious adverse events reported Quality control management extends across R&D, production and sales Collaborate with international Concept design from Europe organization
Slide 13: Development of China Vaccine Quality Management System
Development of China Vaccine Quality Management System New Version of Pharmacopeia for China implemented Oct. 1, 2010 on October 1, 2010 New Version of China GMP standards in compliance End of 2010 with WHO standard to be issued before year end 2010 WHO collaborated with China SFDA to develop July,
Slide 14: Timeline From Development to Commercialization
Timeline From Development to Commercialization Licensed Products From lab to market Market Position Healive 1st inactivated hepatitis A vaccine developed and 7yrs: 1995-2002 manufactured by a Chinese company; inactivated hepatitis A vaccine Bilive 1st combined hepatitis A&B vaccine developed by a 7
Slide 15: Deep Pipeline to Drive Future Growth
Deep Pipeline to Drive Future Growth Pipeline Current Milestone Market Potential Human Vaccines 1.34 million cases reported in China with 736 EV71 (hand, foot, and mouth Filed clinical trial in 2009 • Human clinical trials fatalities by end of July) disease) Vaccine application accepted by – 736 f
Slide 16: Near Term Pipeline - EV71 Inactivated Vaccine
Near Term Pipeline - EV71 Inactivated Vaccine HFMD Epidemic Situation Overview Occurs mainly in children under 6 years old 1600000 800 Majority of reported cases proved to be caused by EV71 Reported Cases 736 Majority of serious and fatal cases caused by EV71,which has 1400000 700 higher fatal incid
Slide 17: Near Term Pipeline – PCV
Near Term Pipeline – PCV Pneumococcal Conjugate Vaccine (PCV) Overview Target Children ＜ 2 years old Population Leading vaccine-preventable killer of children under 5 years old, ~40 million children aged 2 and under in at least 1 million pediatric fatalities every year, according to WHO China Vaccin
Slide 18: Fund Raising and Use of Proceeds
Fund Raising and Use of Proceeds Research & Development Capacity Expansion M&A, Collaboration 2010-2012 Three Investment Areas Issued 11.50 million common shares @ $5.75 per share to raise $62 million in Feb. 2010 Cash balance at June 30, 2010: ~$100 million, bank loan $11.2 million 18
Slide 19: Experienced and Committed Management Team
Experienced and Committed Management Team Over 60 years of combined vaccine industry experience Management Highlights: Proven entrepreneurial success Expertise in operating high growth company Strong capability to develop and commercialize vaccines High standards of corporate governance R&
Slide 20: Financial Performance
Financial Performance Revenue Gross Profit and Margin1 $90 $84 $70 64.13 90% $80 81.9% $60 80% $70 81% 79% 76% (US$m) (US$m) $60 $50 72% 70% $50 $46 36.56 $40 $40 60% $34 27.04 $30 $30 50% $15 $20 $20 $15 11.12 12.05 $10 40% $10 (US$m) $0 $0 30% 2006 2007 2008 2009 1H 2010 2006 2007 2008 2009 1H 201
Slide 21: Conclusion
Conclusion Hepatitis Vaccine Maximize commercialized portfolio Near Influenza Vaccine Term Outlook 2010 revenue impacted by external market factors Outstanding R&D and Quality Control Benefit from new, improved China GMP standards Long Term Deep pipeline expected to drive rapid future growth Outlook
Slide 22: Thank you!
Thank you! — w sinovac »
Sinovac Biotech — Investor Presentation (October 2010) on 6ix